GleamWall
中文EN

CUE Cue Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1645460 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY401.9%
TTM net income YoY-448.5%
TTM EPS YoY-107.1%
Revenue 3-yr CAGR110.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-387.7%
Net margin-579.9%
FCF margin-143.7%
EBITDA margin-384.0%

Returns

ROE-800.4%
ROA-418.0%
ROIC (approx.)—
Asset turnover0.72x

Leverage & solvency

Liabilities / assets42.9%
Debt / equity0.00x
Current ratio3.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-314.6%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$132,000$7.88M$5.69M$21.94M$2.15M$2.95M$421,000$1.58M
R&D expense$17.02M$49.01M$6.90M$16.53M$4.75M$7.91M$8.55M$7.18M
SG&A expense$29.83M$46.56M$4.15M$3.45M$4.94M$3.68M$4.17M$4.02M
Operating income-$47.10M-$87.69M-$5.35M$1.98M-$7.59M-$8.63M-$12.30M-$9.63M
Interest expense———$2,000$33,000$33,000$100,000—
Net income-$50.02M-$153.07M-$5.18M$1.58M-$7.45M-$8.48M-$12.26M-$9.50M
EBITDA-$47.07M-$87.66M-$4.79M$2.66M-$7.52M-$8.54M-$12.20M-$9.54M
EPS (basic)-4.74-24.14-1.08—-2.22-2.67-4.95—
EPS (diluted)-4.74-24.14-1.08—-2.22-2.67-4.95—
Weighted avg. shares (diluted)10.56M6.34M4.81M—3.36M3.18M2.48M—
Banking
Net interest income-$2,000-$5,000-$4,000-$51,000-$75,000-$45,000-$128,000-$153,000
Balance sheet
Cash & equivalents$57.94M$17.39M$16.38M$27.14M$11.70M$27.49M$13.14M$22.46M
Short-term investments————$6.97M——$0
Receivables$5.13M$5.38M$5.35M$5.55M$387,000$532,000$0$945,000
Current assets$66.71M$26.62M$26.39M$36.98M$25.82M$30.84M$15.93M$25.14M
PP&E, net$225,000$255,000$288,000$241,000$307,000$454,000$523,000$471,000
Total assets$67.25M$30.71M$30.88M$42.21M$31.64M$40.71M$22.25M$32.19M
Current liabilities$19.73M$21.22M$7.39M$13.49M$15.52M$19.25M$15.50M$13.69M
Short-term debt——————$100,000$37,000
Long-term debt———————$0
Total debt———————$37,000
Total liabilities$28.86M$28.40M$9.27M$15.78M$18.40M$22.55M$15.67M$14.69M
Shareholders' equity$38.40M$2.31M$21.61M$26.43M$13.25M$18.16M$6.58M$17.50M
Net debt———————-$22.42M
Shares outstanding7.75M5.23M3.26M3.22M77.78M76.45M61.82M61.82M
Cash flow statement
Operating cash flow-$10.08M-$29.00M-$10.94M-$1.08M-$9.02M-$3.42M-$8.17M-$9.03M
Capital expenditure$0$0$121,000$0$0$27,000$150,000$2,000
Free cash flow-$10.08M-$29.00M-$11.06M-$1.08M-$9.02M-$3.44M-$8.32M-$9.03M
Investing cash flow$0$0-$121,000$7.02M-$6.77M-$27,000-$150,000-$1,000
Financing cash flow$50.63M$30.02M$306,000$9.49M$1,000$17.80M-$1.00M-$932,000
Depreciation & amortization$28,000$33,000$566,000$678,000$76,000$97,000$101,000$98,000
Stock-based compensation$35.48M$23.84M$48,000$610,000$1.53M$1.26M$1.34M$1.56M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.